Cipla's stock rose and reached its highest point in the past year, which it had achieved in the previous trading session.Cipla announced that its subsidiary, Cipla (Jiangsu) Pharmaceutical, located in Qidong, Jiangsu Province, China, underwent an inspection by the United States Food and Drug Administration (USFDA) from February 26 to March 1. The inspection concluded without any observations noted on Form 483, according to Cipla.Additionally, in a separate announcement, Cipla informed the stock exchanges that it has finalized the transfer of its generics business. The transfer occurred as a going concern through a slump sale to Cipla Pharma and Life Sciences Limited, a wholly-owned subsidiary of Cipla, on March 1, 2024.